PremiumCompany AnnouncementsImugene Advances Phase 1 onCARlytics Trial with Dose Escalation Clearance Imugene’s Azer-cel Receives FDA Fast Track Designation for DLBCL Imugene Limited Announces Quotation of New Securities on ASX PremiumCompany AnnouncementsImugene Limited Announces Change in Director’s Interest Imugene Limited Issues Unquoted Equity Securities to Boost Growth Imugene Expands Capital with New Securities Quotation PremiumCompany AnnouncementsImugene Secures A$20 Million to Advance Clinical Trials Imugene Limited Issues Convertible Notes and Warrants to Fund Cancer Immunotherapy Efforts Imugene Releases Shares from Voluntary Escrow